Kotani, Ai

Profile

Dr. Kotani graduated from Kyoto University School of Medicine in 1996. After working at Kyoto University Hospital and Shizuoka City Hospital as a resident of internal medicine, she received PhD from Kyoto University. After working as JSPS research fellow at Kyoto University, Whitehead Institute and as assistant professor at the Institute of Medical Science, the University of Tokyo, she was appointed to be associated professor (principal investigator) at Tokai University. After promotion to be professor at Tokai University School of Medicine, she took her current position at RIMD from 2024.

Publication

1. Kameda K., et al., Hepatic niche leads to aggressive NK-cell leukemia proliferation through transferrin-transferrin receptor 1 axis. BLOOD (2023) 142(4):352-364
2. Kudo K., et al., Secreted phospholipase A2 modifies extracellular vesicles and accelerates B cell lymphoma. Cell Metab, (2022) 34, 615-633.e8.
3. Yamamoto Y., et al., Anti-HBV drug entecavir ameliorates DSS-induced colitis through PD-L1 induction. Pharmacol Res (2022) 179, 105918.
4. Kakizaki M., et al., Human hepatocyte-derived extracellular vesicles attenuate the carbon tetrachloride-induced acute liver injury in mice. Cell Death and Disease (2021) 12, 1010.
5. Kakizaki M., et al., Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model. J Biol Chem (2020) 295, 12449-12460.
6. Kawashima M., et al., PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia (2020) 24-Feb.
7. Higuchi H., et al., Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma. BLOOD (2018) 131, 2552-2567.
8. Yamakawa N., et al., Novel functional small RNAs are selectively loaded onto mammalian Ago1. Nucleic acids research (2014) 42(8), 5289-301.
9. Okuyama K., et al., MicroRNA-126-mediated control of cell fate in B-cell myeloid progenitors as a potential alternative to transcriptional factors. PNAS (2013) 110(33) 13410-13415.
10. Kawamata T., et al., Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor. BLOOD (2012) 119(13), 3123-3127.

Lab